Aviso Financial Inc. Takes Position in argenx SE (NASDAQ:ARGX)

Aviso Financial Inc. acquired a new position in shares of argenx SE (NASDAQ:ARGX) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 293 shares of the company’s stock, valued at approximately $180,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Whipplewood Advisors LLC purchased a new stake in shares of argenx during the fourth quarter valued at about $37,000. Global Retirement Partners LLC lifted its position in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after acquiring an additional 48 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after acquiring an additional 61 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after purchasing an additional 21 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in shares of argenx during the fourth quarter worth $66,000. Institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of NASDAQ ARGX opened at $604.96 on Friday. The stock has a market capitalization of $36.76 billion, a price-to-earnings ratio of -687.45 and a beta of 0.59. The firm’s 50 day simple moving average is $638.53 and its 200-day simple moving average is $595.17. argenx SE has a 12 month low of $349.86 and a 12 month high of $678.21.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Guggenheim boosted their target price on argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. HC Wainwright upped their price objective on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a report on Friday, February 28th. Robert W. Baird increased their price objective on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research report on Tuesday, March 4th. Truist Financial restated a “buy” rating and set a $700.00 price target (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, Wedbush reiterated an “outperform” rating and set a $655.00 price objective on shares of argenx in a research note on Tuesday, December 3rd. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.